Circulating miRNAs and Multivariate Biomarker Signatures in Ovarian Cancer: A Systematic Review
Authors:
- Karen AyacheKaren Ayache
- Ana VieiraAVAna Vieira
- Sofia FragosoSFSofia Fragoso
- Siobhan BrushettSBSiobhan Brushett
- Ioannis GallosIGIoannis Gallos
- Pushpa PatelPPPushpa Patel
- Jonathan KrellJKJonathan Krell
- Paula CunneaPCPaula Cunnea
- Dimitra DionysiouDimitra Dionysiou
- Fátima VazFVFátima Vaz
- Paula M. MendesPMPaula M. Mendes
- Myrtani PieriMyrtani Pieri
Open Access
- 2 October 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8823
Abstract
Ovarian cancer (OC) is the most lethal gynecological malignancy, largely because non-specific symptoms contribute to advanced-stage diagnosis and poor prognosis, underscoring the need for improved non-invasive biomarkers. Circulating microRNAs (c-miRNAs) have emerged as promising candidates for OC detection, risk stratification, prognosis, and treatment monitoring. This systematic review, prospectively registered in PROSPERO (CRD420251230898), evaluated the diagnostic and prognostic performance of c-miRNAs and miRNA-based multivariate signatures. MEDLINE/PubMed, Scopus, and CENTRAL were searched from inception to 30 May 2026. Eligible studies assessed c-miRNAs in serum, plasma, whole blood, or extracellular vesicle fractions from women with confirmed or suspected OC including studies using prediagnostic samples from women subsequently diagnosed with OC. Records were screened, data extracted, and risk of bias evaluated according to the type of result using QUADAS-2 for diagnostic accuracy, QUIPS for prognostic-factor associations, and PROBAST for multivariable prediction models. Of 697 records identified, 91 publications met the inclusion criteria. Most studies used case–control or observational designs and analysed serum or plasma samples. Single c-miRNAs generally showed moderate diagnostic accuracy, whereas multivariate miRNA panels and multimodal models incorporating CA-125 or HE4 generally reported higher AUC values, including in some early-stage cohorts. Frequently reported candidates included members of the miR-200 family, miR-21, miR-1246, miR-125b, miR-145, miR-205, and miR-130a. Prognostic studies associated c-miRNAs with survival, recurrence, treatment response, and chemoresistance, although findings were more heterogeneous than diagnostic findings. Risk-of-bias concerns were common, particularly for patient selection in diagnostic studies, confounding in prognostic-factor analyses, and statistical analysis in prediction-model studies. Overall, c-miRNAs represent promising non-invasive biomarkers for OC, particularly when integrated into multivariate or multimodal models. However, methodological heterogeneity, small cohort sizes, limited external validation, and inconsistent reporting currently restrict clinical translation. Future studies should prioritize standardized pre-analytical and analytical workflows, adequately powered prospective cohorts, and independent multicenter validation.Keywords
Funding Information
- European Union (101214318)
This publication has 101 references indexed in Scilit:
- Value of miR200b and its combination with other biochemical markers in the diagnosis of epithelial ovarian cancerMolecular Biology Reports, 2024
- The evaluation of miR-1181 and miR-4314 as serum microRNA biomarkers for epithelial ovarian cancer diagnosis and prognosisMolecular Biology Reports, 2024
- A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patientsClinical and Translational Oncology, 2024
- Evaluation of miR-22 and miR-21 as diagnostic biomarkers in patients with epithelial ovarian cancer3 Biotech, 2020
- The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian CancerThe American Journal of the Medical Sciences, 2019
- Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancerArchives of Gynecology and Obstetrics, 2018
- Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian CancerPathology and Oncology Research, 2018
- Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer2016
- The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancerTumor Biology, 2016
- MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancerTumor Biology, 2015